Institution Directory

Clinical trials at UCSF

Sites in San Francisco, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1407

Shown on this page

Current sort

Live official records

Conditions: Congestive Heart Failure, Heart Failure, Systolic, Heart Failure, HFrEF - Heart Failure With Reduced Ejection Fraction
Interventions: SRD-001, Placebo; Biological · Drug
Lead sponsor: Sardocor Corp.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 5
States / cities: San Diego, California • San Francisco, California • St Louis, Missouri + 2 more

Conditions: Huntington's Disease
Interventions: Not listed
Lead sponsor: CHDI Foundation, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 35,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2062
U.S. locations: 62
States / cities: Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 54 more

Conditions: Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult, Recurrent Glioblastoma, Astrocytoma, Malignant, Astrocytoma of Brain
Interventions: Re-resection, Temozolomide, Lomustine, Re-irradiation, Experimental therapy, Best supportive care; Procedure · Drug · Radiation + 1 more
Lead sponsor: Jasper Gerritsen; Other
Eligibility: 18 Years to 90 Years
Enrollment: 464 participants
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: San Francisco, California • Boston, Massachusetts

Conditions: Glioblastoma, High-grade Glioma, Glioblastoma, IDH-wildtype, Glioblastoma, IDH-mutant, Glioblastoma Multiforme, Adult, Astrocytoma, Grade IV, Astrocytoma, Grade III, Astrocytoma, Malignant, Brain Neoplasms, Brain Neoplasm, Primary, Brain Neoplasms, Adult, Brain Neoplasm, Malignant
Interventions: Supramaximal resection, Maximal safe resection; Procedure
Lead sponsor: Jasper Gerritsen; Other
Eligibility: 18 Years to 90 Years
Enrollment: 784 participants
Timeline: 2022 – 2028
U.S. locations: 2
States / cities: San Francisco, California • Boston, Massachusetts

Conditions: Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme of Brain, Astrocytoma, Malignant, Brain Neoplasms, Brain Neoplasms, Adult, Malignant, Brain Neoplasms, Adult, Recurrent Adult Brain Tumor, Recurrent Glioblastoma
Interventions: Awake mapping under local anesthesia, Asleep mapping under general anesthesia, Resection under general anesthesia without mapping; Procedure
Lead sponsor: Erasmus Medical Center; Other
Eligibility: Up to 90 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: San Francisco, California • Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: zevor-cel; Biological
Lead sponsor: CARsgen Therapeutics Co., Ltd.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2034
U.S. locations: 12
States / cities: Phoenix, Arizona • San Francisco, California • Denver, Colorado + 8 more

Conditions: Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Glioblastoma Multiforme of Brain
Interventions: Tumor resection, Tumor biopsy; Procedure
Lead sponsor: Jasper Gerritsen; Other
Eligibility: 18 Years to 90 Years
Enrollment: 564 participants
Timeline: 2023 – 2029
U.S. locations: 2
States / cities: San Francisco, California • Boston, Massachusetts

Conditions: Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, Adult
Interventions: Palliative Care, Tumor biopsy, Tumor resection; Behavioral · Procedure
Lead sponsor: Jasper Gerritsen; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,015 participants
Timeline: 2023 – 2029
U.S. locations: 2
States / cities: San Francisco, California • Boston, Massachusetts

Conditions: Kidney Transplant; Complications, Dialysis; Complications, Physical Disability, Frailty Syndrome
Interventions: Structured Program of exercise for Recipients of Kidney Transplantation (WC), Structured Program of exercise for Recipients of Kidney Transplantation (WC + CG), Usual Care; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 50 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Brain and Central Nervous System Tumors
Interventions: temozolomide, DNA methylation analysis, laboratory biomarker analysis, adjuvant therapy, quality-of-life assessment, radiation therapy; Drug · Genetic · Other + 2 more
Lead sponsor: European Organisation for Research and Treatment of Cancer - EORTC; Network
Eligibility: 18 Years to 120 Years
Enrollment: 751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2029
U.S. locations: 72
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 57 more

Conditions: Leukemia, Acute Lymphoblastic Leukemia, Acute Promyelocytic Leukemia
Interventions: laboratory biomarker analysis; Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Not listed
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 51
States / cities: San Diego, California • San Francisco, California • Lewes, Delaware + 37 more

Conditions: Ventricular Dysfunction, Left
Interventions: Revivent TC; Device
Lead sponsor: BioVentrix; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 20 more

About this UCSF institution page

What this page lists: ClinicalTrials.gov records that list UCSF in San Francisco, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at UCSF

Filter and sort this campus

Live official records

Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)

The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma

Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)

The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)

Structured Program of Exercise for Recipients of Kidney Transplantation

Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)

Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia

BioVentrix Revivent TC™ System Clinical Study

About this UCSF institution page